SCHEMBL29503576

SCHEMBL29503576

CC(C)(C)OC(=O)N1CCN([C@@]2(C#N)CCOC2)CC1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
RECQL P46063 1/20 0.41
CCR2 P41597 1/20 0.38
EPHX2 P34913 1/20 0.37
CTSS P25774 2/20 0.36
GPR119 Q8TDV5 1/20 0.36
CTSD P07339 1/20 0.36
CTSL P07711 1/20 0.36
CTSB P07858 1/20 0.36
CTSK P43235 1/20 0.36
ALDH1A1 P00352 2/20 0.35
MEN1 O00255 1/20 0.35
MAPT P10636 1/20 0.35
KMT2A Q03164 1/20 0.35
HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24394304 1.00 USP2 (0.49) USP2SMN1; SMN2RECQLCCR2EPHX2
SCHEMBL994040 0.92 USP2 (0.55) USP2SMN1; SMN2RECQLCCR2EPHX2
SCHEMBL18406799 0.89 USP2 (0.50) USP2SMN1; SMN2RECQLEPHX2GPR119
SCHEMBL14314348 0.82 USP2 (0.44) USP2SMN1; SMN2RECQLEPHX2GPR119
SCHEMBL2398369 0.82 USP2 (0.59) USP2SMN1; SMN2RECQLEPHX2CTSS
SCHEMBL14306563 0.81 HPGD (0.43) USP2SMN1; SMN2EPHX2CTSSGPR119
SCHEMBL3665241 0.81 HPGD (0.43) USP2SMN1; SMN2EPHX2CTSSGPR119
SCHEMBL14314342 0.80 EPHX2 (0.42) USP2SMN1; SMN2EPHX2GPR119CTSK
SCHEMBL29503574 0.80 USP2 (0.55) USP2SMN1; SMN2RECQLCCR2EPHX2
SCHEMBL24394305 0.80 USP2 (0.55) USP2SMN1; SMN2RECQLCCR2EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4211119-B1 2-AMINOQUINAZOLINES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF MERCK SHARP & DOHME LLC (US) 2026-05-13 EP disclosed
US-12570640-B2 2-aminoquinazolines as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof MERCK SHARP & DOHME LLC (US) 2026-03-10 US disclosed
US-20230303540-A1 2-AMINOQUINAZOLINES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF MERCK SHARP & DOHME LLC (US) 2023-09-28 US disclosed
EP-4211119-A1 2-AMINOQUINAZOLINES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF Merck Sharp & Dohme LLC (US) 2023-07-19 EP disclosed
WO-2022051337-A1 2-AMINOQUINAZOLINES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF MERCK SHARP & DOHME CORP. (US) 2022-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12570640-B2 2-aminoquinazolines as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof LRRK2, PARK7, CLK2 USP2 3785/4885SMN1; SMN2 689/4885RECQL 483/4885
US-20230303540-A1 2-AMINOQUINAZOLINES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF LRRK2, CLK2, BRSK2 USP2 3313/4885SMN1; SMN2 676/4885RECQL 195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.